Monoclonal antibodies have revolutionized the treatment landscape for immune-mediated inflammatory diseases (IMIDs) such as Crohn’s disease (CD), rheumatoid arthritis (RA), and psoriasis (PsO). These biologic therapies, targeting key inflammatory pathways, offer hope to many patients. However, a critical challenge persists: the inability to predict which patients will respond to a specific biologic treatment. Less than 40% of patients experience a primary response to any given therapeutic, leading to treatment failures that result in disease complications, increased healthcare costs, and diminished quality of life. This unpredictability underscores the urgent need for validated predictive biomarkers to guide personalized medicine in IMIDs.
The METHYLOMIC project aims to address this challenge by leveraging epigenetic biomarkers, particularly DNA methylation profiles, to predict treatment response in patients with CD and potentially other IMIDs. Building on previous cohort studies, our research has identified and validated differential DNA methylation profiles in peripheral blood as biomarkers of response to three approved biologics in CD. These profiles have shown the potential to predict treatment response with up to 93% accuracy. METHYLOMIC is dedicated to translating these findings into clinical practice, advancing personalized treatment selection for CD and beyond. To achieve this, METHYLOMIC has brought together a consortium of clinical experts, epigenetic researchers, DNA diagnostics specialists, patient organizations, and industry partners across Europe. The project undertakes extensive clinical validation studies to ensure that our predictive algorithm-supported epigenetic biomarker assay meets the rigorous regulatory standards required for clinical approval. Additionally, we aim to develop a rapid, market-ready targeted methylation assay, which will be validated through a unique prospective randomized clinical trial for CD.
The ultimate goal of METHYLOMIC is to reduce the burden of Crohn’s disease by accelerating the clinical application of a predictive epigenetic biomarker assay. By enabling a more accurate selection of the most suitable biological therapy for individual patients, this assay is expected to significantly improve treatment outcomes, reduce healthcare costs, and enhance the quality of life for patients. METHYLOMIC’s impact extends beyond the immediate clinical benefits. By providing a validated tool for personalized medicine in CD, the project aligns with broader strategic goals of reducing the burden of chronic diseases, improving patient care, and making healthcare more efficient and cost-effective. The successful implementation of this assay in clinical practice could serve as a model for personalized treatment in other IMIDs, further amplifying its significance.
